Senior Vice President, Clinical Operations
FHI Clinical to write clinical trial protocol for development of Gb Sciences’ COVID-19-related anti-inflammatory therapies
May 2, 2022
FHI Clinical Inc. announces today it will consult on the go-to-market strategy for COVID-19 related anti-inflammatory therapeutics for Gb Sciences. FHI Clinical will additionally write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.